HONG KONG – A Chinese vaccine maker may have to destroy $65 million worth of vaccines because the CFDA refused to give it a release approval for its human rabies vaccine, but the company accused the CFDA of not following its own rules.
HONG KONG – A Chinese pharmaceutical company and its American partner have announced their plan to accelerate collaboration on the development of cancer drugs, with an eye on launching clinical trials in China soon.
HONG KONG – Several major players in China's biopharmaceutical industry have released their second quarter and first-half 2014 financial results, with some companies having a better year than others so far.
HONG KONG – A Chinese biopharma has received approval from South Korean regulators to conduct local clinical trials on its biosimilar drug. Genor Biopharma Co. Ltd., a subsidiary of Walvax Biotechnology Co. Ltd. since last October, received clinical trial approval from the Korean Ministry of Food and Drug Safety (MFDS) for GB232, a biosimilar version of Abbvie Inc.'s Humira.
HONG KONG – Several major players in China's biopharmaceutical industry have released their second quarter and first-half 2014 financial results, with some companies having a better year than others so far.
HONG KONG – A Chinese pharmaceutical company and its American partner have announced their plan to accelerate collaboration on the development of cancer drugs, with an eye on launching clinical trials in China soon.
HONG KONG – Shenyang, China-based 3SBio Inc. has entered an exclusive licensing agreement with Korean biotech Dinona Inc. for 3SBio to develop, manufacture and market leukotuximab in Greater China to offer better treatment to Chinese leukemia patients and reinforce its blood-related disorders pipeline.
HONG KONG – A small Chinese biopharmaceutical company expects that the support and resources of a traditional Chinese medicine (TCM) and active pharmaceutical ingredients manufacturer will help it develop a stronger biologics pipeline.
Walvax Biotechnology Co. Ltd. (SZ:300142) raised an additional ¥450 million (US$73 million) through a private placement. The private placement of 15 million shares will be offered to Li Yunchun, one of Walvax's major shareholders, as well as investment companies Yuxi Gaoxin Private Capital Management, Shenzhen Deruntianqing Investment Management Partnership and Yuxi Runtai Investment Management Partnership.
